LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
LifeMD, Inc.NASDAQ: LFMD
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $549.84K (cash outflow) fell 72.2% year over year, behind the +153.0% change in trailing-twelve-month accounts receivables. Sequentially, it rose 19.7% from the prior quarter.
Context
- Accounts receivables amounted to 0.6% of revenue in FY2025, down 0.8 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -72.2% toward the trailing-twelve-month pace of +153.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.15M USD
- Year-over-year change
- +139.1%
- 4-year CAGR
- +183.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.15M | +139.1% |
| FY2024 | 2024-12-31 | (2.94M) | -20.4% |
| FY2023 | 2023-12-31 | (2.44M) | -11.4% |
| FY2022 | 2022-12-31 | (2.19M) | -12487.8% |
| FY2021 | 2021-12-31 | 17.7K | — |
Accounts Receivables vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +153.0% is the 3rd highest of 10, against a peer median of -82.2%.
- Accounts receivables amounts to 1.2% of revenue for LFMD, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.43M USD | +537.2% | +141.9% | 28.1% | |
| LTM Apr 2026 | CA$5.01M CAD | -470.6% | -28.9% | 0.7% | |
| LTM Mar 2026 | $3.19M USD | -13.2% | -65.0% | 1.4% | |
| LTM Mar 2026 | $2.87M USD | -1376.9% | -66.6% | 5.0% | |
| LTM Mar 2026 | $2.58M USD | +153.0% | — | 1.2% | |
| LTM Mar 2026 | $1.96M USD | +157.2% | — | 1.8% | |
| LTM Mar 2026 | $1.14M USD | -118.2% | — | 1.4% | |
| LTM Mar 2026 | $622K USD | -80.6% | -37.3% | 0.2% | |
| LTM Mar 2026 | $92K USD | -82.2% | -22.0% | 0.2% | |
| LTM Mar 2026 | $86K USD | -93.0% | — | 0.2% | |
| Peer median (excluding LFMD) | — | -82.2% | -33.1% | 1.4% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (61.32M) | (45.02M) | (20.6M) | (18.73M) | 15.62M |
| Depreciation & Amortization | 868.76K | 3.77M | 6.6M | 9.49M | 328.37K |
| Deferred Income Tax | 0 | 354K | 0 | 0 | 0 |
| Stock-Based Compensation | 12.07M | 13.73M | 12.49M | 12.23M | 10.5M |
| Change in Working Capital | 9.13M | (1.55M) | 4.91M | 12.65M | (7.85M) |
| Accounts Receivables | 17.7K | (2.19M) | (2.44M) | (2.94M) | 1.15M |
| Inventory | (409.82K) | (2.18M) | 764.33K | 675.67K | 303.24K |
| Accounts Payables | (893.96K) | 1.25M | 978.06K | 4.92M | 3.24M |
| Other Working Capital | 10.42M | 1.58M | 5.61M | 9.99M | (12.55M) |
| Other Non-Cash Items | 6.17M | 5.78M | 5.42M | 1.87M | (10.31M) |
| Operating Cash Flow | (33.09M) | (22.94M) | 8.82M | 17.51M | 8.28M |
| Capital Expenditures | (3.4M) | (12.89M) | (8.73M) | (11.54M) | (9.52M) |
| Acquisitions (Net) | 0 | (1.01M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.15M) | (12.53M) | (8.53M) | (10.05M) | 8.78M |
| Investing Cash Flow | (3.4M) | (13.91M) | (8.73M) | (11.54M) | 6.91M |
| Debt Repayment | (530.82K) | 2.74M | 16.67M | (327.6K) | (18.72M) |
| Common Stock Issued | 13.99M | 0 | 16.2M | 0 | 9.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (871.48K) | (3.11M) | (3.11M) | (3.11M) | (3.11M) |
| Other Financing Activities | 707.36K | (159.2K) | (667.63K) | (684.83K) | (773.66K) |
| Financing Cash Flow | 68.64M | (528.2K) | 29.1M | (4.12M) | (13.41M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 32.15M | (37.37M) | 29.19M | 1.86M | 1.78M |
| Free Cash Flow | (36.49M) | (35.83M) | 86.95K | 5.98M | (1.24M) |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.